David Bridges
New analysis launched on Wednesday means that Ozempic and comparable medicines could have sudden uncomfortable side effects. Medical doctors in Massachusetts have discovered a hyperlink between the drug’s energetic ingredient semaglutide and the next danger of a uncommon situation that may trigger blindness known as nonarteritic anterior ischemic optic neuropathy (NAION). The findings don’t show a causal connection between the 2, nonetheless, and extra analysis is required to know for sure, the researchers say.
The examine was performed by ophthalmologists at Harvard Medical College and Mass Eye and Ear, a specialty hospital centered on eye points affiliated with Harvard. The staff was impressed to look into the potential hyperlink after they’d come throughout three sufferers who started to lose their imaginative and prescient from NAION inside per week’s time. This may already be unusual, since NAION isn’t quite common (estimates counsel that about 6,000 new instances within the U.S. happen yearly), however all three sufferers have been additionally taking semaglutide.
The researchers determined to do a deep dive into their current knowledge. They analyzed the medical information of about 17,000 Mass Eye and Ear sufferers courting again to 2017, when the primary semaglutide-based treatment Ozempic was authorized to be used as a therapy for kind 2 diabetes. These days, Ozempic can also be used as an off-label treatment for weight reduction together with Wegovy, a higher-dose model of semaglutide authorized for weight problems. Semaglutide and comparable medicine have confirmed to be way more efficient at serving to individuals drop pounds than weight-reduction plan and train alone.
They centered on almost 1,700 sufferers who have been identified with diabetes or with being chubby/overweight however who had no prior historical past of NAION. Then they tracked NAION diagnoses between equally matched teams of sufferers who have been prescribed semaglutide or who have been prescribed different diabetes or weight problems medicines.
The sufferers have been tracked for about three years. Throughout that point, 46 NAION instances have been identified among the many matched teams of sufferers. However these prescribed semaglutide have been considerably extra prone to be identified with NAION, the researchers discovered. This sample was seen throughout each teams of sufferers, although the danger appeared greater for these prescribed the drug for weight reduction. In comparison with individuals taking different weight problems medicines, the danger of NAION was over seven instances greater for these prescribed semaglutide.
“This examine’s findings counsel an affiliation between semaglutide and NAION,” the medical doctors wrote of their paper, printed Wednesday within the journal JAMA Ophthalmology.
So far as the researchers know, that is the primary piece of proof ever to counsel that semaglutide may elevate the danger of NAION. However they’re fast to level out that their work alone can’t present a cause-and-effect relationship between semaglutide and NAION, particularly because it’s based mostly on retrospective, observational knowledge. And there are different caveats to the findings.
The info obtainable solely tracks whether or not individuals have been prescribed these medicines, for example, not whether or not they took them or continued to take them all through the complete examine interval. Given its focus, Mass Eye and Ear additionally sees many extra uncommon eye instances than can be anticipated within the basic inhabitants. On the identical time, the small variety of NAION instances seen within the examine makes it tough to quanify the precise added danger doubtlessly posed by semaglutide (even a number of instances in a single path or the opposite would drastically change the danger ratio). Scientists additionally don’t totally perceive why NAION occurs, a lot much less how these medicine might be elevating individuals’s danger of it. That mentioned, semaglutide mimics the hormone GLP-1, which binds to receptors discovered within the cells of the optic nerve, doubtlessly explaining how issues may come up, the researchers defined.
Whereas NAION is uncommon general, it’s the second commonest explanation for blindness as a result of optic nerve harm, in response to the scientists. And given the surging recognition of those GLP-1 medicine and far greater relative danger of NAION seen on this examine, extra intensive analysis is required to know whether or not this potential complication is actual or not. Bigger retrospective research with knowledge collected from a number of places, randomized scientific trials that comply with sufferers over time, or analyses monitoring reported opposed occasions of all GLP-1 medicine are examples of research that might assist affirm or refute their findings, the authors say.
“As this was an observational examine, future examine is required to evaluate causality,” they wrote.
Daniel Mercer
Brandon Fletcher
